Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion - PubMed (original) (raw)
doi: 10.1038/nm730. Epub 2002 Jun 24.
Scott E Strome, Diva R Salomao, Hideto Tamura, Fumiya Hirano, Dallas B Flies, Patrick C Roche, Jun Lu, Gefeng Zhu, Koji Tamada, Vanda A Lennon, Esteban Celis, Lieping Chen
Affiliations
- PMID: 12091876
- DOI: 10.1038/nm730
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
Haidong Dong et al. Nat Med. 2002 Aug.
Erratum in
- Nat Med 2002 Sep;8(9):1039
Abstract
B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in the regulation of cellular and humoral immune responses through the PD-1 receptor on activated T and B cells. We report here that, except for cells of the macrophage lineage, normal human tissues do not express B7-H1. In contrast, B7-H1 is abundant in human carcinomas of lung, ovary and colon and in melanomas. The pro-inflammatory cytokine interferon-gamma upregulates B7-H1 on the surface of tumor cell lines. Cancer cell-associated B7-H1 increases apoptosis of antigen-specific human T-cell clones in vitro, and the apoptotic effect of B7-H1 is mediated largely by one or more receptors other than PD-1. In addition, expression of B7-H1 on mouse P815 tumor increases apoptosis of activated tumor-reactive T cells and promotes the growth of highly immunogenic B7-1(+) tumors in vivo. These findings have implications for the design of T cell-based cancer immunotherapy.
Comment in
- Protect the killer: CTLs need defenses against the tumor.
Freeman GJ, Sharpe AH, Kuchroo VK. Freeman GJ, et al. Nat Med. 2002 Aug;8(8):787-9. doi: 10.1038/nm0802-787. Nat Med. 2002. PMID: 12152031 No abstract available.
Similar articles
- In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
Lee SH, Bar-Haim E, Machlenkin A, Goldberger O, Volovitz I, Vadai E, Tzehoval E, Eisenbach L. Lee SH, et al. Cancer Gene Ther. 2004 Mar;11(3):237-48. doi: 10.1038/sj.cgt.7700678. Cancer Gene Ther. 2004. PMID: 14739939 - Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. Schreiner B, et al. J Neuroimmunol. 2004 Oct;155(1-2):172-82. doi: 10.1016/j.jneuroim.2004.06.013. J Neuroimmunol. 2004. PMID: 15342209 - B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, Kasperbauer JL, Ballman KV, Chen L. Strome SE, et al. Cancer Res. 2003 Oct 1;63(19):6501-5. Cancer Res. 2003. PMID: 14559843 - Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.
Thompson RH, Dong H, Kwon ED. Thompson RH, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s. doi: 10.1158/1078-0432.CCR-06-1868. Clin Cancer Res. 2007. PMID: 17255298 Review. - B7-H1 pathway and its role in the evasion of tumor immunity.
Dong H, Chen L. Dong H, et al. J Mol Med (Berl). 2003 May;81(5):281-7. doi: 10.1007/s00109-003-0430-2. Epub 2003 Apr 30. J Mol Med (Berl). 2003. PMID: 12721664 Review.
Cited by
- In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy.
Mao C, Deng F, Zhu W, Xie L, Wang Y, Li G, Huang X, Wang J, Song Y, Zeng P, He Z, Guo J, Suo Y, Liu Y, Chen Z, Yao M, Zhang L, Shen J. Mao C, et al. Nat Commun. 2024 Nov 9;15(1):9723. doi: 10.1038/s41467-024-54081-9. Nat Commun. 2024. PMID: 39521768 - Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies.
Zhang Y, Wei R, Song G, Yang X, Zhang M, Liu W, Xiong A, Zhang X, Li Q, Yang WJ, Han C, Liu R, Hu C, Wang Q, Zhu J, Shan Y. Zhang Y, et al. MAbs. 2024 Jan-Dec;16(1):2419838. doi: 10.1080/19420862.2024.2419838. Epub 2024 Nov 4. MAbs. 2024. PMID: 39497266 Free PMC article. - A PD-L1-Targeted Probe Cy5.5-A11 for In Vivo Imaging of Multiple Tumors.
Cao XC, Mao XL, Lu SS, Zhu W, Huang W, Yi H, Yuan L, Zhou JH, Xiao ZQ. Cao XC, et al. ACS Omega. 2024 Oct 17;9(43):43826-43833. doi: 10.1021/acsomega.4c06761. eCollection 2024 Oct 29. ACS Omega. 2024. PMID: 39494025 Free PMC article. - Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature.
Oli AN, Adejumo SA, Rowaiye AB, Ogidigo JO, Hampton-Marcell J, Ibeanu GC. Oli AN, et al. J Immunol Res. 2024 Oct 24;2024:8481761. doi: 10.1155/2024/8481761. eCollection 2024. J Immunol Res. 2024. PMID: 39483536 Free PMC article. Review. - Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.
Murray CE, Kornepati AVR, Ontiveros C, Liao Y, de la Peña Avalos B, Rogers CM, Liu Z, Deng Y, Bai H, Kari S, Padron AS, Boyd JT, Reyes R, Clark CA, Svatek RS, Li R, Hu Y, Wang M, Conejo-Garcia JR, Byers LA, Ramkumar K, Sood AK, Lee JM, Burd CE, Vadlamudi RK, Gupta HB, Zhao W, Dray E, Sung P, Curiel TJ. Murray CE, et al. Mol Cancer. 2024 Oct 30;23(1):242. doi: 10.1186/s12943-024-02147-z. Mol Cancer. 2024. PMID: 39478560 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA15083/CA/NCI NIH HHS/United States
- CA37343/CA/NCI NIH HHS/United States
- CA79915/CA/NCI NIH HHS/United States
- CA80782/CA/NCI NIH HHS/United States
- CA82677/CA/NCI NIH HHS/United States
- CA85721/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous